Table 2B.
Patient characteristics: medical history and medication.
|
Non-AF group
(n = 30) |
AF group
(n = 30) |
p -value | |
|---|---|---|---|
| Medical history | |||
| AF burden (months) | 0 | 29.85 ± 28.43 | N/A |
| Ischemic stroke/TIA | 1.14 ± 0.35 | 1.25 ± 0.43 | 0.677 |
| STEMI | 1.20 ± 0.40 | 1.00 ± 0.00 | 0.606 |
| NSTEMI | 1.33 ± 0.47 | 1.33 ± 0.47 | 0.792 |
| Ventricular tachycardia/ventricular fibrillation (%) | 1 (3.3%) | 2 (6.7%) | >0.999 |
| Arterial hypertension (%) | 29 (96.7%) | 29 (96.7%) | >0.999 |
| Pulmonary embolism (%) | 0 (0.0%) | 1 (3.3%) | >0.999 |
| Deep vein thrombosis (%) | 0 (0.0%) | 3 (10.0%) | 0.116 |
| Peripheral arterial disease/aortic plaque (%) | 10 (33.3%) | 13 (43.3%) | 0.594 |
| Left ventricular hypertrophy (%) | 13 (43.3%) | 14 (46.7%) | >0.999 |
| Stable coronary artery disease (%) | 8 (26.7%) | 4 (13.3%) | 0.32 |
| Chronic obstructive pulmonary disease (COPD) (%) | 1 (3.3%) | 5 (16.7%) | 0.141 |
| Obstructive sleep apnea (OSA) (%) | 1 (3.3%) | 0 (0.0%) | >0.999 |
| Severe valvulopathy (%) | 0 (0.0%) | 0 (0.0%) | >0.999 |
| Electrical cardioversion (%) | 0 (0.0%) | 2 (6.7%) | 0.408 |
| Pharmacological cardioversion (%) | 0 (0.0%) | 3 (10.0%) | 0.116 |
| CHADS2-VASc | 3.7 | 3.7 | N/A |
| Medication | |||
| ACE- inhibitor/ARB (%) | 28 (93.3%) | 26 (86.7%) | 0.663 |
| Spironolactone/Eplerenone (%) | 1 (3.3%) | 1 (3.3%) | >0.999 |
| Beta-blocker (%) | 26 (86.7%) | 26 (86.7%) | >0.999 |
| Digoxin (%) | 1 (3.3%) | 1 (3.3%) | >0.999 |
| Proton pump inhibitors (%) | 6 (20.0%) | 13 (43.3%) | 0.083 |
| Antidepressants/Antipsychotics (%) | 0 (0.0%) | 2 (6.7%) | 0.408 |
| Acetylsalicylic acid (%) | 16 (53.3%) | 8 (26.7%) | 0.056 |
| Clopidogrel (%) | 7 (23.3%) | 3 (10.0%) | 0.279 |
| Prasugrel (%) | 1 (3.3%) | 0 (0.0%) | >0.999 |
| Ticagrelor (%) | 0 (0.0%) | 0 (0.0%) | >0.999 |
| Warfarin (%) | 1 (3.3%) | 9 (30.0%) | 0.001 |
| Dabigatran etexilat (%) | 0 (0.0%) | 4 (13.3%) | 0.021 |
| Rivaroxaban (%) | 0 (0.0%) | 0 (0.0%) | >0.999 |
| Apixaban (%) | 0 (0.0%) | 8 (26.7%) | 0.001 |
| Edoxaban (%) | 0 (0.0%) | 1 (3.3%) | >0.999 |
Data in the table are presented as mean ± standard deviation or n (%).
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSTEMI, Non-ST-elevation myocardial infarction; STEMI, ST-Elevation myocardial infarction; TIA, transient ischemic attack.